The efficacy of aspirin in patients with atrial fibrillation: Analysis of pooled data from 3 randomized trials

Archives of Internal Medicine

Volumn 157, Issue 11, 1997, Pages 1237-1240

  Laupacis, Andreas ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 0031006427     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.11.1237     Document Type: Article

References (14)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet. 1989;1:175-178.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
4. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
5. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
6. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992; 327:1406-1412.
7. EAFT Study Group. Secondary prevention of vascular events in patients with non-rheumatic atrial fibrillation and a recent transient ischaemic attack or minor ischaemic stroke. Lancet. 1993;342:1255-1262.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
9. Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108(suppl):352S-359S.
10. The Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin on prevention of stroke in atrial fibrillation. J Stroke Cerebrovasc Dis. 1993;3:181-188.
11. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet. 1994;343:687-691.
12. Yusuf S, Wittes J, Probestfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized trials. JAMA. 1991; 266:93-98.
13. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84.
14. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.